Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 NeoBOMB1 - Advanced Accelerator Applications

Next Previous
Drug Profile

Lutetium-177 NeoBOMB1 - Advanced Accelerator Applications

Alternative Names: 177LuNeoBOMB1; [177Lu] Lu NeoB; [177Lu]-NeoB; AAA 603; lutetium neoB

Latest Information Update: 29 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Erasmus University Rotterdam; National Center for Scientific Research Demokritos
  • Developer Advanced Accelerator Applications; Novartis
  • Class Antineoplastics; Gallium radioisotopes; Neuropeptides; Oligopeptides; Organometallic compounds; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Neuropeptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer; Solid tumours
  • Phase I Breast cancer; Glioblastoma; Prostate cancer
  • No development reported Gastrointestinal stromal tumours

Most Recent Events

  • 02 Jun 2026 Efficacy, adverse events and pharmacokinetics data from a phase-I/II NeoRay trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 28 Apr 2026 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Newly diagnosed, Recurrent) in Israel (IV, Infusion)
  • 27 Nov 2025 Advanced Accelerator Applications completes the Phase-I/II clinical trials in Solid tumours (Late-stage disease) in USA, Austria, France, Netherlands, Spain and United Kingdom (IV) (NCT03872778)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top